Navigation Links
PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting
Date:2/24/2009

ANNAPOLIS, Md., Feb. 24 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Alternext US: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that results from a Phase II study of SparVax(TM) and pharmacokinetic (PK) data for Valortim(R) were presented at the 7th Annual ASM Biodefense and Emerging Diseases Research Meeting, being held in Baltimore, MD, February 22-25, 2009.

David P. Wright, President and Chief Executive Officer of PharmAthene commented, "The ASM conference is among the leading industry meetings of the year for biodefense and we are pleased to be able to showcase advancements in each of our SparVax(TM) and Valortim(R) programs to key policy makers at this important meeting."

"PharmAthene has received tremendous support from a variety of government funding partners, including, the Department of Defense, the Department of Health and Human Services, and the National Institute of Allergy and Infectious Diseases. This unprecedented collaborative effort will help to ensure the development of urgently needed medical countermeasures to meet the biosecurity needs of our Nation and Allies."

SparVax(TM) is a novel second generation recombinant protective antigen (rPA) anthrax vaccine that is being developed for pre and post exposure protection against anthrax infection. Valortim(R), in co-development with Medarex, Inc. (Nasdaq: MEDX), is a fully human monoclonal antibody designed to protect against and treat inhalational anthrax, the most lethal form of illness in humans caused by anthrax.

SparVax(TM) Phase II Clinical Data

Results from a Phase II clinical trial of SparVax(TM) were presented during a poster session by Dr. Matthew Duchars, Chief Scientific Officer for PharmAthene. The Phase II trial was designed t
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel
2. Pharmathene Reports Third Quarter 2008 Financial and Operational Results
3. PharmAthene to Host Third Quarter 2008 Conference Call and Webcast on Thursday, November 13, 2008
4. PharmAthene to Present on Wednesday, November 12th at the 10th Annual Rodman & Renshaw Healthcare Conference
5. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
6. PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
7. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
8. PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008
9. PharmAthene to Present at the UBS Global Life Sciences Conference on Thursday September 25, 2008
10. PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration
11. PharmAthene Reports Second Quarter 2008 Financial and Operational Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Rice University scientists who created a deicing film for ... as a transparent coating for glass. , The ... colleagues could keep glass surfaces from windshields to skyscrapers ... to radio frequencies (RF). , The technology was ... Applied Materials and Interfaces . , The ...
(Date:9/16/2014)... Cardioxyl Pharmaceuticals, Inc. announced today ... to be effective in animal models following oral (capsule) ... infusions that could pave the way for convenient outpatient ... at the Heart Failure Society of America,s (HFSA) 18 ... Vegas . The research, conducted in ...
(Date:9/16/2014)... 2014 CIRTEC Medical Systems’ Board of ... CEO of CIRTEC. , “I am delighted to ... Company.” noted Brian Highley. “The company has made great ... organic growth over the past two years. The goal ... improve and expand the services Cirtec offers its medical ...
(Date:9/16/2014)... 16, 2014   Synthetic Biologics, Inc. ... anti-infective biologic and drug programs targeting specific pathogens ... completion of the Company,s Investor Day in ... irritable bowel syndrome (IBS) program, including its novel, ... In the keynote presentation, Mark Pimentel ...
Breaking Biology Technology:Nanoribbon film keeps glass ice-free 2Cardioxyl Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 3
... CHERRY HILL, N.J., Sept. 21 Nuvilex, Inc. (OTC Bulletin ... venture partner with Reme-Flu(TM), will be incorporating Syn-X9(TM) proprietary delivery ... remedy designed to help prevent and treat flu-type symptoms resulting ... , , The unique attributes ...
... Merrimack Pharmaceuticals, Inc., announced today that Clet Niyikiza, Ph.D., ... Niyikiza comes to Merrimack from GlaxoSmithKline (GSK) where he was ... Niyikiza has extensive drug development experience with a career ... which he has led ten New Drug Application teams that ...
... , , ROCKVILLE, Md., Sept. 21 ... the U.S. Food and Drug Administration (FDA) has approved its Investigational New ... Lateral Sclerosis (ALS or Lou Gehrig,s disease) with its spinal cord stem ... ) , , Neuralstem is the first ...
Cached Biology Technology:Nuvilex, Inc. Announced that Reme-Flu(TM) will Incorporate Proprietary Syn-X9(TM) Delivery Technology into its Product Formulation 2Nuvilex, Inc. Announced that Reme-Flu(TM) will Incorporate Proprietary Syn-X9(TM) Delivery Technology into its Product Formulation 3Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development 2Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial 2Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial 3Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial 4
(Date:9/16/2014)... inherit certain traits from our parents that are pre-determined. ... play out by taking certain drugs or better yet, ... team of researchers at the Boston University School of ... research. , Epigenetics regulates gene expression in a ... which prevent permanent mutations or alterations within the gene ...
(Date:9/16/2014)... Each tree species has its own bacterial identity. That,s ... from other institutions who studied the genetic fingerprints of ... Panamanian island. , "This study demonstrates for the first ... with different ecological strategies possess very different microbial communities ... a former postdoctoral researcher in the UO,s Institute of ...
(Date:9/16/2014)... a 10-km diameter chunk of rock hit the Yukatan peninsula ... the force of 100 teratons of TNT. It left a ... wildfires, global earthquakes and volcanism are widely accepted to have ... of the mammals. But what happened to the plants on ... researchers from the University of Arizona reveals that the meteorite ...
Breaking Biology News(10 mins):Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3Microbiome research shows each tree species has a unique bacterial identity 2Meteorite that doomed the dinosaurs helped the forests bloom 2Meteorite that doomed the dinosaurs helped the forests bloom 3
... a sudden halt, the carbon dioxide already in Earth,s atmosphere ... according to Princeton University-led research published in the journal ... take a lot less carbon than previously thought to reach ... an Earth on which, after 1,800 billion tons of carbon ...
... Think Greenland,s ice sheet is small today? It was ... history from 3-5,000 years ago, according to scientists who studied ... interpreting the Arctic fossil record. "What,s really interesting about this ... 5,000 years ago, maybe as late as 4,000 years ago. The ...
... Gregg, an assistant professor of mechanical engineering and bioengineering ... Computer Science this fall, is a recipient of a ... for research that will combine robot control theory and ... orthotic devices. "According to the American Society of ...
Cached Biology News:Even if emissions stop, carbon dioxide could warm Earth for centuries 2Even if emissions stop, carbon dioxide could warm Earth for centuries 3Greenland's shrunken ice sheet: We've been here before 2Greenland's shrunken ice sheet: We've been here before 3UT Dallas professor wins $2.3 million NIH award 2UT Dallas professor wins $2.3 million NIH award 3
Microlite 2+ Plate, round bottom; an irradiated, high binding surface with enhanced dynamic range, extra high reflectivity and minimal cross talk for low signal luminescent reactions....
... freezers offer a superior sample management ... samples with high capacities. Innovative insulation ... ensure excellent warming protection and ensure ... accessories simplify tracking of sample location ...
...
Verotoxin IIbeta (457)...
Biology Products: